I think most agree it's a tad underwhelming despite identified issues. Early stage sales momentum for a new technology in what is now a big market in dentistry (implants) you would expect to be quite large. I recently asked a young dentist whether they had heard of striate and they hadn't (it's a pretty significant practice doing implants for over a decade). In the end the next stage products should be more significant to OCC success going forward. Well funded but not expecting huge SP appreciation any time soon. GLTA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
-0.010(0.81%) |
Mkt cap ! $301.1M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.22 | $424.0K | 344.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14244 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 24599 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| OCC (ASX) Chart |